Skip to main content

Table 1 Patient characteristics and median survival from the time of treatment initiation, mRCC patients, Estonia 2004–2012

From: Changes in therapy and survival of metastatic renal cell carcinoma in Estonia

 TotalTreatment group 1aTreatment group 2b
N%N%N%p-value
Total380100125100255100 
Age group
 15–591203242347831p = 0.706
 60–691343545368935 
 70+1263338308835 
Sex
 Male25266836616966p = 0.981
 Female1283442348634 
Histology
 Clear Cell31382826623191p < 0.001
 Non-Clear cell61163931229 
 Unknown624321 
Nephrectomy
 Done314831028121283p = 0.712
 Not done611622183915 
 Other511142 
Treatment started
 2004–200713736107863012p < 0.001
 2008–201224364181422588 
Prognostic group (only 2008–2012)
 Favorable5021164922p = 0.03
 Intermediate15363105514364 
 Poor941684 
 Unknown31136332511 
 Median survival in months (95% CI)13.7 (11.3–16.2) 7.6 (6.4–8.6) 19.8 (15.6–22.9) p < 0.001
Survival#
 12-month53% (48–58) 30% (22–38) 65% (59–71)  
 24-month34% (29–38) 14% (9–21) 43% (37–49)  
 36-month24% (20–28) 9% (5–15) 31% (25–37)  
  1. a INFa only
  2. b INFa followed by targeted agents or targeted agents only